NCT04672824 is a Phase 1 clinical trial of ChAdOx1 RVF in RVF, sponsored by University of Oxford.

Who is sponsoring NCT04672824?

NCT04672824 is sponsored by University of Oxford.

What drugs are being tested in NCT04672824?

Interventions in NCT04672824: ChAdOx1 RVF, Saline.

What condition does NCT04672824 study?

NCT04672824 studies RVF, Rift Valley Fever.

Is NCT04672824 still recruiting?

NCT04672824 is currently completed. Last updated 6 February 2023.

Last reviewed 2023-02-06 · How we verify

NCT04672824

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

Completed Phase 1 Last updated 6 February 2023

What this trial tests

Phase 1 trial testing ChAdOx1 RVF in RVF in 30 participants. Completed in 15 December 2022.

Timeline

31 May 2022

Primary endpoint
15 December 2022

15 December 2022

Quick facts

Lead sponsor	University of Oxford
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	prevention
Enrollment	30
Start date	31 May 2022
Primary completion	15 December 2022
Estimated completion	15 December 2022
Sites	1 location across Uganda

Drugs / interventions tested

ChAdOx1 RVF — full drug profile →
Saline

Conditions studied

RVF — all drugs for RVF →
Rift Valley Fever — all drugs for Rift Valley Fever →

Sponsor

University of Oxford

Who can join

Adults 18 to 50, any sex, with RVF or Rift Valley Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021.
Gerken KN, LaBeaud AD, Mandi H, L'Azou Jackson M, et al · · 2022 · cited 59× · PMID 35073355 · DOI 10.1371/journal.pntd.0009852
An Overview of Rift Valley Fever Vaccine Development Strategies.
Kitandwe PK, McKay PF, Kaleebu P, Shattock RJ. · · 2022 · cited 39× · PMID 36366303 · DOI 10.3390/vaccines10111794
Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.
Alkan C, Jurado-Cobena E, Ikegami T. · · 2023 · cited 24× · PMID 37925544 · DOI 10.1038/s41541-023-00769-w
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
Anywaine Z, Serwanga J, Ggayi AM, Abaasa AM, et al · · 2026 · PMID 41237791 · DOI 10.1016/s1473-3099(25)00565-1

Verify or expand the search:

Other trials of ChAdOx1 RVF

Trials testing the same drug.

NCT06799234 — Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) · Phase 2 · active not recruiting
NCT04754776 — Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001) · EARLY_PHASE1 · completed

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04672824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 6 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04672824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing